BioSante

Oppenheimer is making some adjustments to its estimates on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) “We note BPAX's cash balance of ~$51M, which we believe is sufficient to fund operations into 2012,” Oppenheimer writes. “We adjust our 2011 EPS estimate to ($0.69) from ($0.43) and our 2012...

According to Oppenheimer, BioSante Pharmaceuticals (NASDAQ: BPAX) efficacy data is expected in 4Q11. Oppenheimer reported that on 4/7, BPAX held an investor event focused on LibiGel, the company's lead pipeline product for the treatment of Female Sexual Dysfunction (FSD). “Importantly, ~3K women...

In a report published by Oppenheimer, BioSante Pharmaceuticals (NASDAQ: BPAX) reported adjusted EPS of ($0.18) compared to its estimated EPS of ($0.14), owing to higher R&D expenses of ~$12M. Oppenheimer said that it believes potential efficacy data readout in 3Q11 and safety data release in...

LINCOLNSHIRE, Ill. - October 18, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers...

LINCOLNSHIRE, Ill. - September 22, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the JMP Healthcare Conference being held in the New York Palace Hotel, New York City from September 27-28, 2010 Phillip B. Donenberg, BioSante's senior vice president...